妊娠相关急性肾损伤 中国就医指南

Pregnancy-Associated Acute Kidney Injury (PA-AKI) is a sudden, reversible decline in kidney function occurring during pregnancy or within 6 weeks postpartum. Defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria—namely, an increase in serum creatinine ≥0.3 mg/dL within 48 hours, or ≥1.5-fold from baseline within 7 days, or urine output <0.5 mL/kg/h for >6 consecutive hours—PA-AKI represents a critical obstetric and nephrologic emergency. Unlike community-acquired AKI, PA-AKI arises in a uniquely dynamic physiological milieu: pregnancy induces profound hemodynamic, immunologic, and coagulation changes—including systemic vasodilation, increased renal plasma flow (up to 50%), glomerular hyperfiltration, and mild physiological proteinuria—all of which mask early signs of injury and complicate timely diagnosis. Pathogenesis is multifactorial: direct obstetric causes dominate, including preeclampsia/eclampsia (accounting for ~40–60% of cases), HELLP syndrome, placental abruption, sepsis (especially postpartum endometritis), acute fatty liver of pregnancy (AFLP), and postpartum hemorrhage with hypovolemic shock. Less common contributors include thrombotic microangiopathies (e.g., atypical HUS), lupus nephritis flares, and drug-induced nephrotoxicity (e.g., NSAIDs, antibiotics). Epidemiologically, PA-AKI remains rare but life-threatening: global incidence ranges from 0.5 to 5.2 per 10,000 deliveries, with higher rates in low-resource settings (up to 15–20 per 10,000) due to delays in antenatal care and limited access to emergency obstetrics. In high-income countries, incidence is ~1–3 per 10,000 pregnancies, yet mortality remains 5–15%—rising sharply when dialysis is required or multiorgan failure develops. Key risk factors include preexisting chronic kidney disease, hypertension, diabetes mellitus, autoimmune disorders (e.g., SLE), advanced maternal age (>35), multiparity, obesity, and socioeconomic barriers to prenatal care. Importantly, even mild PA-AKI confers long-term risks: up to 30% of survivors develop chronic kidney disease within 5 years, and recurrent pregnancy complications (e.g., preeclampsia, fetal growth restriction) are significantly elevated. Quality of life impact is substantial: patients often experience prolonged hospitalization, psychological distress (anxiety, post-traumatic stress related to near-miss maternal events), breastfeeding disruption, delayed return to work, and heightened caregiver burden. Neonatal outcomes further compound this burden—preterm birth, low birth weight, and neonatal ICU admission occur in >60% of severe PA-AKI cases. Early recognition via serial creatinine monitoring, urinalysis, and Doppler ultrasound—combined with multidisciplinary management involving nephrologists, maternal-fetal medicine specialists, and intensivists—is essential to mitigate irreversible renal damage and optimize both maternal and fetal survival.

# 妊娠相关急性肾损伤（AKI）治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：G1–G2期AKI、血肌酐<265 μmol/L、无严重子痫前期/HELLP综合征、胎儿稳定者。

• •基础支持：液体管理+血压控制（拉贝洛尔/硝苯地平）＋监测尿量/电解质：800–1,500元/周
• •药物干预：促红细胞生成素（EPO）、碳酸氢钠纠酸、利尿剂（呋塞米）：1,200–2,800元/疗程（7–14天）
• •检验检查费（含血常规、肾功、电解质、尿蛋白定量、胎盘生长因子PLGF、sFlt-1）：960–1,350元/次

二、介入/核心治疗方案

适用人群：G3期AKI、少尿/无尿>24h、高钾血症（K⁺≥6.0 mmol/L）、容量超负荷或合并重度子痫前期需紧急肾脏替代治疗。

• •连续性肾脏替代治疗（CRRT）（单机持续72h以上）：12,000–22,000元/周（含管路耗材、抗凝药、护理）
• •术前检查（心脏超声、凝血四项、血型交叉配血、中心静脉置管评估）：2,100–3,400元

三、特殊复杂情况处理

• •合并HELLP综合征或胎盘早剥：多学科联合（产科+ICU+肾内科），CRRT+终止妊娠：总费用35,000–68,000元/住院周期
• •耐药性高血压肾损害或顽固性高钾：加用新型钾结合剂（环硅酸锆钠）：4,500–6,200元/疗程（3–5天）

四、方案快速选择指南

• •预算有限（≤5,000元）：首选保守治疗+严密随访；
• •中等预算（5,000–25,000元）：CRRT短期干预，兼顾母胎安全；
• •危重/多器官受累（≥35,000元）：启动MDT绿色通道，优先保障母婴生命。